Sound-facilitated inner ear drug delivery.
Kainic acid was applied to the round window of young gerbils under different acoustic conditions— in silence or with 60-75 dB SPL sounds. (A) Tuning curves at 30 dB SPL. The CFs of the three probing channels are 9.0, 3.8 and 1.8 kHz. (B) Normalized neural responses in the AVCN versus the time of drug application. The drug effect time, tE, was defined at the 75 percentiles of normalized curves. In this measurement, it took 54 minutes to affect the 3.8 kHz CF location (green dashed line and arrow). (C) DPOAEs were measured before and after the kainic acid delivery. Two stimulating tones were at 40 dB SPL, and the frequency ratio was 1.1. The x-axis is the f1 frequency. (A-C) Example of drug delivered in silence (“Silence” case). (D, E, F) Example of drug delivery during the presentation of broadband noise at 75 dB SPL (“Sound” case). (G) Response curves with colors representing CFs. Basal (higher frequency) responses decay earlier. Out of 82 measurements, 48 silence-case curves are from 18 animals and 34 sound-case curves are from 13 animals. (H) Mean responses of sound and silence cases at similar locations (CF = 4.5-6.5 kHz); n=19 for Silence, and n=13 for Sound. (I) Effect time versus CF location. The shaded frequency range corresponds to the data in panel H. The broken curve (“Trend” line) was obtained by fitting a curve to the silence data using 1D diffusion theory. (J) Effect time in dB with respect to the trend line. tE in dB = 20log10(tE/tTrend). (K) Two-tailed t-tests between the effect times of sound and silence cases for the entire CF range (whole, n=48, 34 for silence and sound), low-CF locations (<4.5 kHz, n=24, 16 for silence and sound), and high-CF locations (> 4.5 kHz, n=24, 18 for silence and sound). Throughout this paper, the symbols and range bars indicate the mean and the 95% confidence interval, respectively.